Research Misconduct – Irresistible Temptation

Temptation is ever-present in the clinical testing environment, and a conflict of interest can turn that temptation into an unacceptable moral act. Impropriety may also take the form of outright fraud as a researcher tries to profit from the lucrative medical research field. When it comes to safeguarding subjects in a clinical trial, the most important body that can insist on ethical behavior are Institutional Review Boards, which review and monitor research studies involving human subjects. There has always been concern over the relationship between clinical investigators and pharmaceutical companies. With all the complex financial relationships between drug companies and researchers, concerns about imprudent behavior cannot be overlooked. A series of case studies show how personal greed can disgrace the proud research profession. The brilliant academic who authored numerous articles in very good journals until it was discovered they were based on fabricated and falsified data. The successful entrepreneur in California who was caught conducting fraudulent research, exposed by his own employees. The phony physician overseeing clinical trials charged and convicted of fraud and criminal negligent homicide, ending up with a six-year jail sentence.


Confl ict of interest ethics fraud misconduct whistleblower 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Chapter 23 — Research Misconduct

Cited References

  1. Beecher H. Ethics and clinical research. New Engl J Med 1966:274;1354–1360.PubMedGoogle Scholar
  2. Davidoff F, DeAngelis C, Drazen J, et al. Sponsorship, authorship, and accountability. Ann Int Med 2001:135;463–465.PubMedGoogle Scholar
  3. Joyce C. Congress slams misconduct in medical research. New Scientist. http://www. 15 Sep 30, 1990.
  4. Krimsky S, Rothenberg L, Stottc P, et al. Scientific journals and their authors' financial interests: a pilot study. Psychother Psychosom 1998:67;194–201.PubMedCrossRefGoogle Scholar
  5. Martinson B, Anderson M, de Vries R. Scientists behaving badly. Nature 2005:435;737–738.PubMedCrossRefGoogle Scholar
  6. McCarty M. Perspectives. Book. Lies, damn lies, and scientific research. Lancet 2004:364; 1657–1658.CrossRefGoogle Scholar
  7. Quick J. Maintaining the integrity of the clinical evidence base. B World Health Organ 2001:79;1093.Google Scholar
  8. Ranstam J, Buyse M, George S, et al. Fraud in medical research: an international survey of bio-statisticians. ISCB subcommittee on fraud. Control Clin Trials 2000:21;415–427.PubMedCrossRefGoogle Scholar
  9. Willman D. Stealth merger: drug companies and government medical research. Los Angeles Times Dec 7, 2003:A1.Google Scholar

General References

  1. Angell M. Is academic medicine for sale? New Engl J Med 2000:342;1516–1518.PubMedCrossRefGoogle Scholar
  2. DeAngelis C, Fontanarosa P, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 2004:286;89–91.CrossRefGoogle Scholar
  3. Eichenwald K. U.S. officials are examining clinical trials. New York Times July 14, 1999:C1.Google Scholar
  4. Eichenwald K, Kolata G. Research for hire. A doctor's drug studies turn into fraud. New York Times May 17, 1999:A1.Google Scholar
  5. Emanual E, Wood A, Fleishman A, et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med 2004:141;282–291.Google Scholar
  6. Health and Human Services. Hearing: avoiding conflicts of interest at the National Institutes of Health. Statement by Ruth Kirchstein, M.D. Jan 22, 2004.
  7. Health and Human Services. Code of Federal Regulations. Part 46 Protection of human subjects. June 23, 2005.
  8. Ioannidis J, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001:285;437–443.PubMedCrossRefGoogle Scholar
  9. Judson H. The great betrayal: fraud in science. New York: Harcourt, 2004.Google Scholar
  10. Lurie P, Almedia C, Stine N, et al. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. JAMA 2006:295; 1921–1928.PubMedCrossRefGoogle Scholar
  11. Miller F, Rosenstein D, DeRenzo E. Professional integrity in clinical research. JAMA 1998:280; 1449–1454.PubMedCrossRefGoogle Scholar
  12. National Institutes of Health. Conflict of interest information and resources. Oct 26, 2006.
  13. National Institutes of Health. NIH history. Aug 1, 2006.
  14. Schneider W. The establishment of institutional review boards in the U.S. http://www.iupui. edu/~histwhs/G504.dir/irbhist.html Jan 3, 2006.
  15. Sontag D. Abuses endangered veterans in cancer drug experiments. New York Times Feb 6, 2005:A1.Google Scholar
  16. Warlow C. Clinical research under the cosh again. Brit Med J 2004:329;241–242.PubMedCrossRefGoogle Scholar
  17. Weiss R. U.S. researchers reach deal in '99 gene therapy case. Washington Post Feb 10, 2005:A3.Google Scholar

Copyright information

© Springer Science + Business Media B.V 2009

Personalised recommendations